Liquid biopsy is a non-invasive technology that identifies molecular biomarkers using liquid sample instead of using costly or invasive procedures. These tests have great potential for primary detection of cancer, treatment and recurrence monitoring, recognition of genetic abnormalities in foetus, and graft rejection in transplantation patients.
Demand Scenario
The global liquid biopsy market was USD 1074.73 million in 2018 and is estimated to reach USD 2832.96 million by 2025 at a CAGR of 14.85% during the forecast period
Growth by Region
North America leads the market owing to the innovative technological improvements, and increasing occurrence of cancer rates in the Canada and U.S. The markets in developing countries are likely to grow at a rapid pace during the forecast period owing to the rising disease prevalence, healthcare awareness, and healthcare spending.
Drivers and Restraints
Growth in research & developments and clinical trials for diagnostics, technological enhancements, growing occurrence of cancer, and growing awareness about liquid biopsy are the major factors fostering the market growth. However, huge costs and complex regulations are restraining the market growth.
Industry Trends and Updates
According to the study of World Health Organization, nearly 14 million new cancer cases were diagnosed and is anticipated to grow by about 70% over the next 2 decades.
Global Liquid Biopsy Market – by Clinical Applications, Product and Services, Cancer Types, Circulating Biomarkers Covered, Sample Types, End Users, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2018 - 2025)
1. Research Methodology
2. Executive Summary
3. Market Overview
3.1. Definition
3.2. Industry Value Chain Analysis
3.3. Porter's 5 Forces
3.4. Regulations
4. Market Dynamics
4.1. Introduction
4.2. Drivers
4.3. Constraints
4.4. Trends
5. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Clinical Applications
5.1. Treatment Monitoring
5.2. Recurrence Monitoring
5.3. Early Cancer Screening
5.4. Therapy Selection
6. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Product and Services
6.1. Platforms and Instruments
6.2. Assay Kits & Reagents
6.3. Services
7. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Cancer Types
7.1. Breast Cancer
7.2. Liver Cancer
7.3. Lung Cancer
7.4. Colorectal Cancer
7.5. Others
8. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Circulating Biomarkers Covered
8.1. Circulating Tumour DNA (CTDNA)
8.2. Extracellular Vesicles (Evs)
8.3. Circulating Tumour Cells
8.4. Cell-Free DNA
8.5. Exosomes
8.6. Others
9. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Sample Types
9.1. Urine
9.2. Blood
9.3. Others
10. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by End Users
10.1. Academic and Research Centre
10.2. Hospitals and Physician Laboratories
10.3. Diagnostic Centres and Reference Laboratories
11. Global Liquid Biopsy Market Segmentation, Forecasts and Trends - by Region
11.1. North America
11.1.1. U.S.
11.1.2. Canada
11.1.3. Mexico
11.2. Europe
11.2.1. Germany
11.2.2. UK
11.2.3. Italy
11.2.4. France
11.2.5. Spain
11.2.6. Others
11.3. Asia Pacific
11.3.1. Japan
11.3.2. China
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Others
11.4. South America
11.4.1. Argentina
11.4.2. Brazil
11.4.3. Chile
11.4.4. Others
11.5. Middle East and Africa
11.5.1. Saudi Arabia
11.5.2. UAE
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Others
12. Competitive Intelligence
12.1. Company Market Share Analysis
12.2. Industry M&As, Consolidations
13. Company Profiles
13.1. Roche Diagnostics
13.2. Guardant Health Inc.
13.3. Illumina Inc.
13.4. Biocept Inc.
13.5. Myriad Genetics Inc.
13.6. Qiagen N.V.
13.7. Trovagene, Inc.
13.8. Menarini Silicon Biosystems
13.9. Genomic Helath Inc.
13.10. MDxHealth SA
13.11. RainDance Technologies, Inc.
13.12. Thermo Fisher Scientific Inc.
13.13. Bio-Rad Laboratories Inc.
13.14. Epic Sciences
13.15. Exosome
13.16. Cynvenio
13.17. Guardant Health
13.18. Personal Genome Diagnostics
13.19. Janssen Diagnostics LLC
13.20. Others
14. Investment Opportunities
